Wells Fargo & Company Cytosorbents Corp Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding CTSO
# of Institutions
53Shares Held
17.8MCall Options Held
0Put Options Held
0-
Avenir Corp Washington, DC3.17MShares$3.84 Million0.27% of portfolio
-
Granahan Investment Management, LLC Waltham, MA3.04MShares$3.68 Million0.1% of portfolio
-
Skylands Capital, LLC2.84MShares$3.44 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$2.36 Million0.0% of portfolio
-
Neuberger Berman Group LLC New York, NY1.91MShares$2.31 Million0.0% of portfolio
About Cytosorbents Corp
- Ticker CTSO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 43,577,400
- Market Cap $52.7M
- Description
- Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...